Please login to the form below

Not currently logged in
Email:
Password:

Digital intelligence blog

Pharma insight on digital marketing, social media, mobile apps, online video, websites and interactive healthcare tools

Boehringer partners with PatientsLikeMe on rare disease community

Collaborates with the online patient community on idiopathic pulmonary fibrosis

Boehringer Ingelheim PatientsLikeMe IPF

Boehringer Ingelheim is collaborating with the online patient community PatientsLikeMe on the rare lung condition idiopathic pulmonary fibrosis (IPF).

The partnership, announced to coincide with last week's Rare Diseases Day, will see Boehringer help enhance PatientsLikeMe's existing IPF community.

This will take the form of providing what PatientsLikeMe says will be a “customised experience” for its users that will allow them monitor their health and progress over time and connect with others to learn more about the condition.

PatientsLikeMe co-founder and president Ben Heywood said: “We are excited to partner with Boehringer Ingelheim, a leading pharmaceutical company, to support this patient initiative.

“Rare diseases are sometimes called 'orphan diseases' because they affect so few people, and don't attract significant research attention or funding. Our website is where patients count. They're contributing their real-world experience to help others living with IPF and advance research.”

In pulmonary fibrosis deep lung tissue becomes scarred over time, making it harder for the lungs to move oxygen into the bloodstream. Cases where the cause of the disease is unknown are called IPF, which has no known cause, treatment or cure.

IPF usually affects middle-aged and older adults and in the US an estimated 100,000 people have the condition.

4th March 2013

From: Healthcare

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Biosector 2

Biosector 2 (B2) is a global healthcare public relations agency that partners with visionary clients to deliver groundbreaking programs and...

Latest intelligence

More of the same: The importance of strategic communications planning for biosimilar entry
GCI Health's Hannah Morris considers the importance of strategic communications planning for biosimilar entry, a market anticipated to deliver between €8-26bn in savings across the European Union by 2020....
Online Physician Communities
How can pharma realise the power of digital?
Firstly, by making it owned and driven by the most senior leadership team in the business...
Remapping the market: Does Pharma's global model need a shake up?
For patients, carers and professionals, wherever they are in the world, digital technology is inherent in their everyday lives. Digital is, so to speak, a global language. The success of...